Solid Biosciences (SLDB) Receivables - Other (2020 - 2022)
Quarterly results put Receivables - Other at $14000.0 for Q1 2022, down 95.0% from a year ago — trailing twelve months through Mar 2022 was $14000.0 (down 95.0% YoY), and the annual figure for FY2021 was $110000.0, changed.
Solid Biosciences has reported Receivables - Other over the past 3 years, most recently at $14000.0 for Q1 2022.
- Receivables - Other reached $14000.0 in Q1 2022 per SLDB's latest filing, down from $110000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $594000.0 in Q3 2021 and bottomed at $14000.0 in Q1 2022.
- Median Receivables - Other over the past 3 years was $283000.0 (2020), compared with a mean of $261666.7.
- The largest annual shift saw Receivables - Other changed 0.0% in 2021 before it tumbled 95.0% in 2022.
- Over 3 years, Receivables - Other stood at $286000.0 in 2020, then tumbled by 61.54% to $110000.0 in 2021, then crashed by 87.27% to $14000.0 in 2022.
- Business Quant data shows Receivables - Other for SLDB at $14000.0 in Q1 2022, $110000.0 in Q4 2021, and $594000.0 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 110,000.00 |
| Dec 31, 2021 | 110,000.00 |
| Sep 30, 2021 | 594,000.00 |
| Sep 30, 2021 | 594,000.00 |
| Jun 30, 2021 | 286,000.00 |
| Jun 30, 2021 | 286,000.00 |
| Mar 31, 2021 | 280,000.00 |
| Mar 31, 2021 | 280,000.00 |
| Jun 30, 2020 | 286,000.00 |
| Jun 30, 2020 | 286,000.00 |